Locations:
Search IconSearch
May 10, 2022/Opinion

Why we now use a race-free algorithm to predict kidney disease

Media Contact

Cleveland Clinic News Service | 216.444.0141

We’re available to shoot custom interviews & b-roll for media outlets upon request.

Media Downloads

CCNS health and medical content is consumer-friendly, professional broadcast quality (available in HD), and available to media outlets each day.

hemodialysis in people on the equipment
Crystal Gadegbeku, M.D.

In a cleveland.com op-ed, Crystal Gadegbeku, M.D. — chair of the Department of Kidney Medicine in the Glickman Urological and Kidney Institute at Cleveland Clinic — explains the importance of not using race as a biomarker in determining a person’s kidney function.

“Because of the inherent bias in using race as a factor,” she writes, “the National Kidney Foundation and the American Society of Nephrology led a task force to find a better equation that estimates kidney function without a race variable.”

To read the complete op-ed, visit cleveland.com.

Latest from the Newsroom

Beri Ridgeway, M.D.

Cleveland Clinic Appoints Beri Ridgeway, M.D., as President of Cleveland Clinic London

Genediting Therapy Shows Success Against Severe Sickle Cell Disease

Gene Editing Therapy Shows Success Against Severe Sickle Cell Disease

Cleveland Clinic's Main Campus lobby

Mandel Foundation Donates $50 Million to Improve Access to Care at Cleveland Clinic

Blood pressure cuff

Experimental Monthly Injectable Reduces a Key Regulator of Blood Pressure

GLP-1 injection pen with a stethoscope

Tirzepatide Associated with Lower Risk of Heart and Kidney Damage Compared to Dulaglutide in Patients with Type 2 Diabetes and Cardiovascular Disease

Hospital Care At Home

Cleveland Clinic Introduces Hospital Care At Home in Ohio

Image of a scaled and tape measure

What Happens When Patients Stop Taking GLP-1 Drugs? New Cleveland Clinic Study Reveals Real World Insights

Illustration of digital medical records

AI-Driven Chart Review Accurately Identifies Potential Rare Disease Trial Participants in New Study